Claims for Patent: 10,705,095

Summary for Patent: 10,705,095

Title:	Methods and products for evaluating an immune response to a therapeutic protein
Abstract:	The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
Inventor(s):	Subramanyam; Meena (Stoneham, MA), Amaravadi; Lakshmi (Natick, MA), Wakshull; Eric (Princeton, MA), Lynn; Frances (Somerville, MA), Panzara; Michael (Winchester, MA), Barbour; Robin McDaid (Walnut Creek, CA), Taylor; Julie Elizabeth (San Francisco, CA)
Assignee:	BIOGEN MA INC. (Cambridge, MA)
Application Number:	15/616,669
Patent Claims:	1. A method, comprising: (a) administering natalizumab to a subject having Multiple Sclerosis; (b) detecting in a first biological sample obtained from the subject at a first time point the presence or absence of at least a threshold level of anti-natalizumab antibody binding activity; and (c) detecting in a second biological sample obtained from the subject at a second time point the presence or absence of at least a threshold level of anti-natalizumab antibody binding activity, wherein the threshold level is equal to the level of anti-natalizumab antibody binding activity present in a reference sample comprising at least 500 ng/ml of anti-natalizumab antibody. 2. The method of claim 1, wherein the first time point is at least 12 weeks following step (a). 3. The method of claim 1, wherein the second time point is at least 42 days following the first time point. 4. The method of claim 1 further comprising identifying the subject for continued treatment with natalizumab if: (i) the anti-natalizumab antibody binding activity detected in step (b) is present at or above the threshold level and if the anti-natalizumab antibody binding activity detected in step (c) is absent or present below the threshold level; or (ii) the anti-natalizumab antibody binding activity detected in step (b) is absent or present below the threshold level and if the anti-natalizumab antibody binding activity detected in step (c) is absent or present below the threshold level. 5. The method of claim 1 further comprising identifying the subject for modified or discontinued treatment with natalizumab if the anti-natalizumab antibody binding activity detected in step (b) is present at or above the threshold level and if the anti-natalizumab antibody binding activity detected in step (c) is present at or above the threshold level. 6. The method of claim 1, wherein the level of anti-natalizumab antibody binding activity in step (b) and/or in step (c) is detected using a bridging enzyme-linked immunosorbent assay (ELISA) assay. 7. A method, comprising: (a) administering natalizumab to a subject having Multiple Sclerosis; (b) detecting in a first serum sample obtained from the subject at a first time point of at least 12 weeks following the administration of natalizumab, the presence or absence of at least a threshold level of anti-natalizumab antibody binding activity; and (c) detecting in a second serum sample obtained from the subject at a second time point of at least 42 days following the first time point, the presence or absence of at least a threshold level of anti-natalizumab antibody binding activity, wherein the threshold level is equal to the level of anti-natalizumab antibody binding activity present in a reference sample comprising at least 500 ng/ml of anti-natalizumab antibody. 8. (v) The method of claim 7 further comprising identifying the subject for continued treatment with natalizumab if: (i) the anti-natalizumab antibody binding activity detected in step (b) is present at or above the threshold level and if the anti-natalizumab antibody binding activity detected in step (c) is absent or present below the threshold level; or (ii) the anti-natalizumab antibody binding activity detected in step (b) is absent or present below the threshold level and if the anti-natalizumab antibody binding activity detected in step (c) is absent or present below the threshold level. 9. The method of claim 7 further comprising identifying the subject for modified or discontinued treatment with natalizumab if the anti-natalizumab antibody binding activity detected in step (b) is present at or above the threshold level and if the anti-natalizumab antibody binding activity detected in step (c) is present at or above the threshold level. 10. The method of claim 8, wherein the level of anti-natalizumab antibody binding activity in step (b) and/or in step (c) is detected using a bridging ELISA assay. 11. The method of claim 9, wherein the level of anti-natalizumab antibody binding activity in step (b) and/or in step (c) is detected using a bridging ELISA assay. 12. A method, comprising: (a) obtaining at a first time point a first biological sample from a subject that has been administered natalizumab; (b) detecting in the first biological sample the presence or absence of at least a threshold level of anti-natalizumab antibody binding activity; (c) obtaining at a second time point a second biological sample from the subject; and (d) detecting in the second biological sample the presence or absence of at least a threshold level of anti-natalizumab antibody binding activity, wherein the threshold level of step (b) and step (d) is equal to the level of anti-natalizumab antibody binding activity present in a reference sample comprising at least 500 ng/ml of anti-natalizumab antibody. 13. The method of claim 12, wherein the first time point is at least 12 weeks following step (a). 14. The method of claim 12, wherein the second time point is at least 42 days following the first time point. 15. The method of claim 12 further comprising identifying the subject for continued treatment with natalizumab if: (i) the anti-natalizumab antibody binding activity detected in step (b) is present at or above the threshold level and if the anti-natalizumab antibody binding activity detected in step (c) is absent or present below the threshold level; or (ii) the anti-natalizumab antibody binding activity detected in step (b) is absent or present below the threshold level and if the anti-natalizumab antibody binding activity detected in step (c) is absent or present below the threshold level. 16. The method of claim 12 further comprising identifying the subject for modified or discontinued treatment with natalizumab if the anti-natalizumab antibody binding activity detected in step (b) is present at or above the threshold level and if the anti-natalizumab antibody binding activity detected in step (c) is present at or above the threshold level. 17. The method of claim 12, wherein the level of anti-natalizumab antibody binding activity in step (b) and/or in step (c) is detected using a bridging enzyme-linked immunosorbent assay (ELISA) assay. 18. A method, comprising: (a) obtaining at a first time point a first serum sample from a subject having Multiple Sclerosis that has been administered natalizumab, wherein the first time point is at least 12 weeks following administration of natalizumab; (b) detecting in the first serum sample the presence or absence of at least a threshold level of anti-natalizumab antibody binding activity, wherein the threshold level of step (b) is equal to the level of anti-natalizumab antibody binding activity present in a reference sample comprising at least 500 ng/ml of anti-natalizumab antibody; (c) obtaining at a second time point a second serum sample from the subject, wherein the second time point is at least 42 days following the first time point; and (d) detecting in the second serum sample the presence or absence of at least a threshold level of anti-natalizumab antibody binding activity, wherein the threshold level of step (d) is equal to the level of anti-natalizumab antibody binding activity present in a reference sample comprising at least 500 ng/ml of anti-natalizumab antibody. 19. The method of claim 18 further comprising identifying the subject for continued treatment with natalizumab if: (i) the anti-natalizumab antibody binding activity detected in step (b) is present at or above the threshold level and if the anti-natalizumab antibody binding activity detected in step (d) is absent or present below the threshold level; or (ii) the anti-natalizumab antibody binding activity detected in step (b) is absent or present below the threshold level and if the anti-natalizumab antibody binding activity detected in step (d) is absent or present below the threshold level. 20. The method of claim 18 further comprising identifying the subject for modified or discontinued treatment with natalizumab if the anti-natalizumab antibody binding activity detected in step (b) is present at or above the threshold level and if the anti-natalizumab antibody binding activity detected in step (d) is present at or above the threshold level. 21. The method of claim 19, wherein the level of anti-natalizumab antibody binding activity in step (b) and/or in step (d) is detected using a bridging ELISA assay. 22. The method of claim 20, wherein the level of anti-natalizumab antibody binding activity in step (b) and/or in step (c) is detected using a bridging ELISA assay.

Details for Patent 10,705,095

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2025-04-04